Genetic aspects of hepatocellular carcinogenesis

Seminars in Liver Disease

Volumn 19, Issue 3, 1999, Pages 235-242

  Ozturk, Mehmet ^a  

^a BILKENT UNIVERSITY   (Turkey)

Author keywords

Cyclin D; Hepatocellular carcinoma; M6P IGF2R; P16INK4A; p53; Primary liver cancer; catenin

Indexed keywords

AFLATOXIN; BETA CATENIN; CARCINOGEN; CYCLIN A; CYCLIN D; PROTEIN P53;

ARTICLE; GENE MUTATION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER INJURY; PRIORITY JOURNAL; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; VIRUS ONCOGENE;

EID: 0032847563     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007113     Document Type: Article

References (104)

1. Ozturk M. Biology of hepatocellular carcinoma. In: AK Rustgi, ed. Gastrointestinal Cancers, Biology, Diagnosis, and Therapy. Philadelphia, PA: Lippincott-Raven, 1995, pp 511-525
2. Buendia MA. Hepatitis B viruses and hepatocellular carcinoma. Adv Cancer Res 1992;59:167-226
3. Idilman R, De Maria N, Colantoni A, Van Thiel DH. Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma. J Viral Hepat 1998;5:285-299
4. Puisieux A, Ozturk M. TP53 and hepatocellular carcinoma. Pathol Biol (Paris) 1997;45:864-870
5. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991;350:429-431
6. Hsu IC, Metcalf RA, Sun T, et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350:427-428
7. Coursaget P, Depril N, Chabaud M, et al. High prevalence of mutations at codon 249 of the p53 gene in hepatocellular carcinomas from Senegal. Br J Cancer 1993;67:1395-1397
8. Ozturk M, Puisieux A, Kew M, et al. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991;338: 1356-1359
9. Unsal H, Yakicier C, Marcais C, et al. Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci USA 1994; 91:822-826
10. Li D, Cao Y, He L, Wang NJ, Gu JR. Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis 1993;14:169-173
11. Fujimoto Y, Hampton LL, Wirth PJ, et al. Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China. Cancer Res 1994;54:281-285
12. Greenblatt MS, Feitelson MA, Zhu M, et al. Integrity of p53 in hepatitis B x antigen-positive and -negative hepatocellular carcinomas. Cancer Res 1997;57:426-432
13. Wang XW, Forrester K, Yen H, et al. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA 1994;91: 2230-2234
14. Ueda H, Ullrich SJ, Gangemi JD, et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 1995;9:41-47
15. Elmore LW, Hancock AR, Chang SF, et al. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci USA 1997;94:14707-14712
16. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-4878
17. Prives C. Signalling to p53: breaking the MDM2-p53 circuit. Cell 1998;95:5-8
18. Reed SI. Control of the G1/S transition. Cancer Surv 1997; 29:7-23
19. Johnson DG, Schneider-Broussard R. Role of E2F in cell cycle control and cancer. Front Biosci 1998;3:447-448
20. Razin A. CpG methylation, chromatin structure and gene silencing - a three-way connection. EMBO J 1998;17:4905-4908
21. De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995;11:447-449
22. Thorgeirsson SS, Teramoto T, Factor VM. Dysregulation of apoptosis in hepatocellular carcinoma. Semin Liver Dis 1998; 18:115-122
23. Derynck R, Zhang Y, Feng XH. Smads: Transcriptional activators of TGF-beta responses. Cell 1998;95:737-740
24. Kawate S, Takenoshita S, Ohwada S, et al. Mutation analysis of transforming growth factor type II receptor, smad2, and smad4 in hepatocellular carcinoma. Int J Oncol 1999;14:127-131
25. Yakicier MC, Irmak MB, Romano A, Kew M, Ozturk M. Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene (in press).
26. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-170
27. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275:1787-1790
28. Peifer M. Beta-catenin as oncogene: the smoking gun. Science 1997;275:1752-1753
29. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 1998;153:333-339
30. de La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998;95: 8847-8851
31. Miyoshi Y, Iwao K, Nagasawa Y, et al. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 1998;58:2524-2547
32. Horii A, Nakatsuru S, Miyoshi Y, et al. Frequent somatic mutations of the APC gene in human pancreatic cancer. Cancer Res 1992;52:6696-6698
33. Kuraliashi H, Takami K, Oue T, et al. Biallelic inactivation of the APC gene in hepatoblastoma. Cancer Res 1995;55:5007-5011
34. Giardiello FM, Petersen GM, Brensinger JD, et al. Hepatoblastoma and APC gene mutation in familial adenomatous polyposis. Gut 1996;39:867-869
35. Gruner BA, DeNapoli TS, Andrews W, Tomlinson G, Bowman L, Weitman SD. Hepatocellular carcinoma in children associated with Gardner syndrome or familial adenomatous polyposis. J Pediatr Hematol Oncol 1998;20:274-278
36. Piao Z, Choi Y, Park C, Lee WJ, Park JH, Kim H. Deletion of the M6P/IGF2r gene in primary hepatocellular carcinoma. Cancer Lett 1997;120:39-43
37. Oda H, Imai Y, Nakatsuru Y, Hata J, Ishikawa T. Somatic mutations of the APC gene in sporadic hepatoblastomas. Cancer Res 1996;56:3320-3323
38. Rainier S, Dobry CJ, Feinberg AP. Loss of imprinting in hepatoblastoma. Cancer Res 1995;55:1836-1838
39. Li X, Adam G, Cui H, Sandstedt B, Ohlsson R, Ekstrom TJ. Expression, promoter usage and parental imprinting status of insulin-like growth factor II (IGF2) in human hepatoblastoma: uncoupling of IGF2 and H19 imprinting. Oncogene 1995;11:221-229
40. Takeda S, Kondo M, Kumada T, et al. Allelic-expression imbalance of the insulin-like growth factor 2 gene in hepatocellular carcinoma and underlying disease. Oncogene 1996;12:1589-1592
41. Kim KS, Lee YI. Biallelic expression of the H19 and IGF2 genes in hepatocellular carcinoma. Cancer Lett 1997;119:143-148
42. Li X, Kogner P, Sandstedt B, Haas OA, Ekstrom TJ. Promoter-specific methylation and expression alterations of igf2 and h19 are involved in human hepatoblastoma. Int J Cancer 1998;75: 176-180
43. Li X, Nong Z, Ekstrom C, et al. Disrupted IGF2 promoter control by silencing of promoter P1 in human hepatocellular carcinoma. Cancer Res 1997;57:2048-2054
44. Yamada T, De Souza AT, Finkelstein S, Jirtle RL. Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci USA 1997;94:10351-10355
45. Murakami Y, Hayashi K, Hirohashi S, Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 1991;51:5520-5525
46. Nakamura T, Iwamura Y, Kaneko M, et al. Deletions and rearrangements of the retinoblastoma gene in hepatocellular carcinoma, insulinoma and some neurogenic tumors as found in a study of 121 tumors. Jpn J Clin Oncol 1991;21:325-329
47. Nishida N, Fukuda Y, Kokuryu H, et al. Accumulation of allelic loss on arms of chromosomes 13q, 16q and 17p in the advanced stages of human hepatocellular carcinoma. Int J Cancer 1992;51:862-868
48. Zhang X, Xu HJ, Murakami Y, et al. Deletions of chromosome 13q, mutations in retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 1994;54:4177-4182
49. Ashida K, Kishimoto Y, Nakamoto K, et al. Loss of heterozygosity of the retinoblastoma gene in liver cirrhosis accompanying hepatocellular carcinoma. J Cancer Res Clin Oncol 1997;123:489-495
50. Iolascon A, Giordani L, Moretti A, Basso G, Borriello A, Della Ragione F. Analysis of CDKN2A, CDKN2B, CDKN2C, and cyclin Ds gene status in hepatoblastoma. Hepatology 1998; 27:989-995
51. Lin YW, Chen CH, Huang GT, et al. Infrequent mutations and no methylation of CDKN2A (P16/MTS1) and CDKN2B (p15/MTS2) in hepatocellular carcinoma in Taiwan. Eur J Cancer 1998;34:1789-1795
52. Kita R, Nishida N, Fukuda Y, et al. Infrequent alterations of the p16INK4A gene in liver cancer. Int J Cancer 1996;67:176-180
53. Chaubert P, Gayer R, Zimmermann A, et al. Germ-line mutations of the p16INK4(MTS1) gene occur in a subset of patients with hepatocellular carcinoma. Hepatology 1997; 25: 1376-1381
54. Kim, JR, Kim SY, Kim MJ, Kim JH. Alterations of CDKN2 (MTS1/p16INK4A) gene in paraffin-embedded tumor tissues of human stomach, lung, cervix and liver cancers. Exp Mol Med 1998;30:109-114
55. Furutani M, Arii S, Tanaka H, et al. Decreased expression and rare somatic mutation of the CIP1/WAF1 gene in human hepatocellular carcinoma. Cancer Lett 1997;111:191-197
56. Zhang YJ, Jiang W, Chen CJ, et al. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun 1993;196:1010-1016
57. Nishida N, Fukuda Y, Komeda T, et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res 1994;54:3107-3110
58. Wang J, Chenivesse X, Henglein B, Brechet C. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature 1990;343:555-557
59. Chao Y, Shih YL, Chiu JH, et al. Overexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma. Cancer Res 1998;58:985-890
60. Slagle BL, Zhou YZ, Birchmeier W, Scorsone KA. Deletion of the E-cadherin gene in hepatitis B virus-positive Chinese hepatocellular carcinomas. Hepatology 1993;18:757-762
61. Kanai Y, Ushijima S, Hui AM, et al. The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Int J Cancer 1997;71:355-359
62. Katagiri T, Nakamura Y, Miki Y. Mutations in the BRCA2 gene in hepatocellular carcinomas. Cancer Res 1996;56:4575-4577
63. Macdonald GA, Greenson JK, Saito K, Cherian SP, Appelman HD, Boland CR. Microsatellite instability and loss of heterozygosity at DNA mismatch repair gene loci occurs during hepatic carcinogenesis. Hepatology 1998;28:90-97
64. De Benedetti VM, Welsh JA, Trivers GE, et al. p53 is not mutated in hepatocellular carcinomas from Alaska Natives. Cancer Epidemiol Biomarkers Prev 1995;4:79-82
65. Shieh YS, Nguyen C, Vocal MV, Chu HW. Tumor-suppressor p53 gene in hepatitis C and B virus-associated human hepatocellular carcinoma. Int J Cancer 1993;54:558-562
66. Goldblum JR, Bartos RE, Carr KA, Frank TS. Hepatitis B and alterations of the p53 tumor suppressor gene in hepatocellular carcinoma. Am J Surg Pathol 1993;17:1244-1251
67. Kazachkov Y, Khaoustov V, Yoffe B, Solomon H, Klintmalm GB, Tabor E. p53 abnormalities in hepatocellular carcinoma from United States patients: Analysis of all 11 exons. Carcinogenesis 1996;17:2207-2212
68. De Benedetti VM, Welsh JA, Yu MC, Bennett WP. p53 mutations in hepatocellular carcinoma related to oral contraceptive use. Carcinogenesis 1996;17:145-159
69. Honda K, Sbisa E, Tullo A, et al. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br J Cancer 1998; 77:776-782
70. Soini Y, Chia SC, Bennett WP, et al. An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis 1996;17:1007-1012
71. Kennedy SM, Macgeogh C, Jaffe R, Spurr NK. Overexpression of the oncoprotein p53 in primary hepatic tumors of childhood does not correlate with gene mutations. Hum Pathol 1994;25: 438-442
72. Kubicka S, Trautwein C, Schrem H, Tillmann H, Manns M. Low incidence of p53 mutations in European hepatocellular carcinomas with heterogeneous mutation as a rare event. J Hepatol 1995;23:412-419
73. Kress S, Jahn UR, Buchmann A, Bannasch P, Schwarz M. p53 mutations in human hepatocellular carcinomas from Germany. Cancer Res 1992;52:3220-3223
74. Pontisso P, Belluco C, Bertorelle R, et al. Hepatitis C virus infection associated with human hepatocellular carcinoma: Lack of correlation with p53 abnormalities in Caucasian patients. Cancer 1998;83:1489-1494
75. Challen C, Lunec J, Warren W, Collier J, Bassendine MF. Analysis of the p53 tumor suppressor gene in hepatocellular carcinomas from Britain. Hepatology 1992;16:1362-1366
76. Yumoto Y, Hanafusa T, Hada H, et al. Loss of heterozygosity and analysis of mutation of p53 in hepatocellular carcinoma. J Gastroenterol Hepatol 1995;10:179-185
77. Debuire B, Paterlini P, Pontisso P, Basso G, May E. Analysis of the p53 gene in European hepatocellular carcinomas and hepatoblastomas. Oncogene 1993;8:2303-2306
78. Scorsone KA, Zhou YZ, Butel JS, Slagle BL. p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res 1992;52:1635-1638
79. Yang M, Zhou H, Kong RY, et al. Mutations at codon 249 of p53 gene in human hepatocellular carcinomas from Tongan, China. Mutat Res 1997;381:25-29
80. Ng IO, Srivastava G, Chung LP, Tsang SW, Ng MM. Overexpression and point mutations of p53 tumor suppressor gene in hepatocellular carcinomas in Hong Kong Chinese people. Cancer 1994;74:30-37
81. Lunn RM, Zhang YJ, Wang LY, et al. p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatoceliular carcinoma in Taiwan. Cancer Res 1997;57:3471-3477
82. Diamantis ID, McGandy C, Chen TJ, Liaw YF, Gudat F, Bianchi L. A new mutational hot-spot in the p53 gene in human hepatocellular carcinoma. J Hepatol 1994;20:553-556
83. Sheu JC, Huang GT, Lee PH, et al. Mutation of p53 gene in hepatocellular carcinoma in Taiwan. Cancer Res 1992;52:6098-6100
84. Shi CY, Phang TW, Lin Y, et al. Codon 249 mutation of the p53 gene is a rare event in hepatocellular carcinomas from ethnic Chinese in Singapore. Br J Cancer 1995;72:146-149
85. Hollstein MC, Wild CP, Bleicher F, et al. p53 mutations and aflatoxin B1 exposure in hepatocellular carcinoma patients from Thailand. Int J Cancer 1993;53:51-55
86. Hayashi H, Sugio K, Matsumata T, et al. Tanaka S, Sugimachi K The mutation of codon 249 in the p53 gene is not specific in Japanese hepatocellular carcinoma. Liver 1993;13:279-281
87. Nose H, Imazeki F, Ohto M, Omata M. p53 gene mutations and 17p allelic deletions in hepatocellular carcinoma from Japan. Cancer 1993;72:355-360
88. Tanaka S, Toh Y, Adachi E, Matsumata T, Mori R, Sugimachi K. Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. Cancer Res 1993;53:2884-2887
89. Vesey DA, Hayward NK, Cooksley WG. p53 gene in hepatocellular carcinomas from Australia. Cancer Detect Prev 1994;18:123-130
90. Tsuda H, Hirohashi S, Shimosato Y, Ino Y, Yoshida T, Terada M. Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma. Jpn J Cancer Res 1989;80:196-199
91. Tada M, Omata M, Ohto M. Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing. Cancer Res 1990;50:1121-1124
92. Stork P, Loda M, Bosari S, Wiley B, Poppenhusen K, Wolfe H. Detection of K-ras mutations in pancreatic and hepatic neoplasms by non-isotopic mismatched polymerase chain reaction. Oncogene 1991;6:857-862
93. Challen C, Guo K, Collier JD, Cavanagh D, Bassendine MF. Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas. J Hepatol 1992;14:342-346
94. Lin SY, Chen PH, Wang CK, et al. Mutation analysis of K-ras oncogenes in gastroenterologic cancers by the amplified created restriction sites method. Am J Clin Pathol 1993;100:686-689
95. Leon M, Kew MC. Analysis of ras gene mutations in hepatocellular carcinoma in southern African blacks. Anticancer Res 1995;15:859-861
96. Zhang XK, Huang DP, Qiu DK, Chiu JF. The expression of c-myc and c-N-ras in human cirrhotic livers, hepatocellular carcinomas and liver tissue surrounding the tumors. Oncogene 1990;5:909-914
97. Ogata N, Kamimura T, Asakura H. Point mutation, allelic loss and increased methylation of c-Ha-ras gene in human hepatocellular carcinoma. Hepatology 1991;13:31-37
98. Bjersing L, Andersson C, Lithner F. Hepatocellular carcinoma in patients from northern Sweden with acute intermittent porphyria: morphology and mutations. Cancer Epidemiol Biomarkers Prev 1996;5:393-397
99. Tsuda H, Shimosato Y, Upton MP, et al. Retrospective study on amplification of N-myc and c-myc genes in pediatric solid tumors and its association with prognosis and tumor differentiation. Lab Invest 1988;59:321-327
100. Abou-Elella A, Gramlich T, Fritsch C, Gansler T. c-myc amplification in hepatocellular carcinoma predicts unfavorable prognosis. Mod Pathol 1996;9:95-98
101. Mares J, Polanska V, Gorgens H, et al. Oncogene amplification and expression in pediatric solid tumors. Neoplasma 1998;45:123-127
102. Nishida N, Fukuda Y, Kokuryu H, et al. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma. Cancer Res 1993;53:368-372
103. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 1992;52:6358-6364
104. Kang YK, Kim CJ, Kim WH, Kim HO, Kang GH, Kim YI. p53 mutation and overexpression in hepatocellular carcinoma and dysplastic nodules in the liver. Virchows Arch 1998;432:27-32